Piper Jaffray Raises Price Target on Endo Int'l (ENDP) Leading up to Par Pharma Acquisition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Endo to Acquire Par Pharmaceutical, Strategically Expanding Generics Business to a Top 5 Industry Leader
May 18, 2015 6:30 AM EDTDUBLIN and WOODCLIFF LAKE, N.J., May 18, 2015 /PRNewswire/ --
Transaction valued at $8.05 billion is transformative for Endo, creating a powerful platform for future growth and further strategic M&A Creates specialty pharmaceutical company with one of industry's fastest growing generics businesses and expanded product portfolio, pipeline, technology platform and manufacturing capabilities Positions Endo for long-term double-digit organic growth, strong cash flow and financial flexibility Accretive to non-GAAP diluted earnings per share within first 12 months with double-digit accretion to non-GAAP diluted earnings per... MoreEndo Announces Updated XIAFLEX® Label with Recurrence and Retreatment Data in Patients with Dupuytren's Contracture
May 15, 2015 5:38 PM EDTDUBLIN, May 15, 2015 /PRNewswire/ -- Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ: ENDP) (TSX: ENL), today announced that the U.S. Food and Drug Administration (FDA) has approved a label update for XIAFLEX® (collagenase clostridium histolyticum or CCH) for the treatment of adult Dupuytren's contracture (DC) patients with a palpable cord. The updated label now includes a long-term, observational study demonstrating the rate of recurrence for up to 5 years after successful treatment with XIAFLEX®, and the efficacy and safety of... More
